Geron Co. (NASDAQ:GERN) Shares Bought by Wellington Management Group LLP

Wellington Management Group LLP increased its holdings in shares of Geron Co. (NASDAQ:GERN - Free Report) by 4.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,662,404 shares of the biopharmaceutical company's stock after buying an additional 570,580 shares during the period. Wellington Management Group LLP owned about 2.09% of Geron worth $57,487,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in GERN. State Street Corp lifted its holdings in Geron by 28.4% during the third quarter. State Street Corp now owns 28,961,671 shares of the biopharmaceutical company's stock valued at $131,486,000 after purchasing an additional 6,413,204 shares in the last quarter. Stifel Financial Corp raised its position in shares of Geron by 30.7% during the 3rd quarter. Stifel Financial Corp now owns 47,477 shares of the biopharmaceutical company's stock worth $216,000 after purchasing an additional 11,149 shares during the last quarter. Readystate Asset Management LP purchased a new position in Geron in the 3rd quarter valued at about $58,000. RTW Investments LP acquired a new stake in Geron in the 3rd quarter worth about $200,268,000. Finally, Iron Triangle Partners LP purchased a new stake in Geron during the 3rd quarter worth approximately $15,214,000. Institutional investors and hedge funds own 73.71% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. HC Wainwright restated a "buy" rating and issued a $9.00 target price on shares of Geron in a research report on Tuesday. Scotiabank assumed coverage on Geron in a report on Wednesday, October 16th. They issued a "sector outperform" rating and a $6.00 price objective on the stock. Leerink Partnrs raised shares of Geron to a "strong-buy" rating in a report on Monday, September 9th. Leerink Partners assumed coverage on shares of Geron in a research note on Monday, September 9th. They issued an "outperform" rating and a $7.00 price target on the stock. Finally, Barclays raised shares of Geron to a "strong-buy" rating in a research note on Friday, November 29th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $7.15.

Geron Trading Down 2.0 %

NASDAQ:GERN traded down $0.08 on Thursday, hitting $3.90. The stock had a trading volume of 4,321,695 shares, compared to its average volume of 10,139,579. The company has a fifty day moving average price of $4.08 and a two-hundred day moving average price of $4.34. Geron Co. has a 1-year low of $1.64 and a 1-year high of $5.34. The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04. The stock has a market cap of $2.36 billion, a price-to-earnings ratio of -12.44 and a beta of 0.51.

Geron (NASDAQ:GERN - Get Free Report) last posted its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.05. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The company had revenue of $28.27 million during the quarter, compared to analysts' expectations of $18.97 million. During the same quarter last year, the firm earned ($0.08) earnings per share. The firm's quarterly revenue was up 17138.4% compared to the same quarter last year. Equities research analysts expect that Geron Co. will post -0.25 earnings per share for the current fiscal year.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.